Global Stroke Management

Stroke Management Comprehensive Study by Type (Ischemic, Hemorrhagic, Transient Ischemic Attack (TIA))), Application (Hospitals, Ambulatory Surgery Centers, Diagnostic Centers), Diagnostics (Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Electrocardiography, Carotid Ultrasound, Cerebral Angiography, Others), Therapeutics (Antiplatelet, Tissue Plasminogen Activator, Antihypertensive, Anticoagulant), Devices (Stent Retriever, Surgical Clipping, Embolic Coils, Flow Diverters, Aspiration Catheters) Players and Region - Global Market Outlook to 2026

Stroke Management Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 7.03%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The prevalence of heart failures, mental and physical strokes have prevailed drastically across the globe. This will ultimately encourage healthcare institutes to minimize heart failure instances. The global stroke management market will show further growth with respect to the increasing adoption of Magnetic Resonance Imaging [MRI], Computed Tomography Scan [CT Scan], Electrocardiography, Carotid Ultrasound, Cerebral Angiography, and many others. In addition to this, the global population has seen numerously unfavorable and unhealthier habits which will ultimately require the use of heart failure testing tools. Furthermore, increasing government initiatives and reimbursements on intensive R&Ds has further escalated the growth of the stroke management industry.

AttributesDetails
Study Period2017-2027
Base Year2021
High Growth MarketAsia Pacific
UnitValue (USD Billion)
Key Companies ProfiledGE Healthcare (United States), Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), Toshiba Corporation (Japan), Shimadzu Corporation (Japan), Hitachi, Ltd. (Japan), Neurologica Corporation (United States), Neusoft Medical Systems Co. Ltd. (China), Shenzhen Anke High-tech Co. (China) and Shanghai United Imaging Healthcare Co. Ltd. (China)


According to AMA, the market for Stroke Management is expected to register a CAGR of 7.03% during the forecast period to 2027. This growth is primarily driven by Growth of Research and Developments in Tackling Critical Heart Diseases and Rising Prevalence of Cardio-Vascular Diseases across the Globe.

Globally, a noticeable market trend is evident Growing Affordability of Cardio Vascular Treatments and Increasing Disposable Incomes The Health Care Technology sector in the North Amercia region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as GE Healthcare (United States), Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), Toshiba Corporation (Japan), Shimadzu Corporation (Japan), Hitachi, Ltd. (Japan), Neurologica Corporation (United States), Neusoft Medical Systems Co. Ltd. (China), Shenzhen Anke High-tech Co. (China) and Shanghai United Imaging Healthcare Co. Ltd. (China), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The global Stroke Management market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. Key vendors with a prominent share in the global market are concentrating on escalating their client base the world. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability. Key vendors operating in the global market are also acquiring start-ups.

On February 7th, 2019, the global cardiac monitoring devices provider Medotronic Inc. has received U.S. Food and Drug Administration (FDA) approval on an expanded indication for its Pipeline(TM) Flex embolization device.1Previously indicated for the endovascular treatment of adults with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments, the new indication opens options for patients with small or medium, wide-necked brain aneurysms in the territory from the petrous to the terminus of the internal carotid artery.

Influencing Trend:
Growing Affordability of Cardio Vascular Treatments and Increasing Disposable Incomes and Introduction to Highly Efficient Cardiac Biomarkers and Minimally Invasive Stroke Management Tools

Market Growth Drivers:
Growth of Research and Developments in Tackling Critical Heart Diseases and Rising Prevalence of Cardio-Vascular Diseases across the Globe

Challenges:
Operational Complexities and the Dearth of Skilled Researchers and Need to improve the devices’ clinician interface threatened continuous growth and profitability

Restraints:
Technological Hindrance with Respect to Collection and Storage of Samples and Stringent Government Regulations on Approval and Use of Medical Devices

Opportunities:
Increasing R&D Infrastructure in Healthcare across the Developing Nations and Rising Consumer Eagerness towards Healthcare Expenditure

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Stroke Management Market
- Analysis about New Entrants in Stroke Management Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Stroke Management Study Sheds Light on
— The Stroke Management Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Stroke Management industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Stroke Management industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Ischemic
  • Hemorrhagic
  • Transient Ischemic Attack [TIA])
By Application
  • Hospitals
  • Ambulatory Surgery Centers
  • Diagnostic Centers
By Diagnostics
  • Magnetic Resonance Imaging [MRI]
  • Computed Tomography Scan [CT Scan]
  • Electrocardiography
  • Carotid Ultrasound
  • Cerebral Angiography
  • Others

By Therapeutics
  • Antiplatelet
  • Tissue Plasminogen Activator
  • Antihypertensive
  • Anticoagulant

By Devices
  • Stent Retriever
  • Surgical Clipping
  • Embolic Coils
  • Flow Diverters
  • Aspiration Catheters

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth of Research and Developments in Tackling Critical Heart Diseases
      • 3.2.2. Rising Prevalence of Cardio-Vascular Diseases across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Operational Complexities and the Dearth of Skilled Researchers
      • 3.3.2. Need to improve the devices’ clinician interface threatened continuous growth and profitability
    • 3.4. Market Trends
      • 3.4.1. Growing Affordability of Cardio Vascular Treatments and Increasing Disposable Incomes
      • 3.4.2. Introduction to Highly Efficient Cardiac Biomarkers and Minimally Invasive Stroke Management Tools
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Stroke Management, by Type, Application, Diagnostics, Therapeutics, Devices and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Stroke Management (Value)
      • 5.2.1. Global Stroke Management by: Type (Value)
        • 5.2.1.1. Ischemic
        • 5.2.1.2. Hemorrhagic
        • 5.2.1.3. Transient Ischemic Attack [TIA])
      • 5.2.2. Global Stroke Management by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgery Centers
        • 5.2.2.3. Diagnostic Centers
      • 5.2.3. Global Stroke Management by: Diagnostics (Value)
        • 5.2.3.1. Magnetic Resonance Imaging [MRI]
        • 5.2.3.2. Computed Tomography Scan [CT Scan]
        • 5.2.3.3. Electrocardiography
        • 5.2.3.4. Carotid Ultrasound
        • 5.2.3.5. Cerebral Angiography
        • 5.2.3.6. Others
      • 5.2.4. Global Stroke Management by: Therapeutics (Value)
        • 5.2.4.1. Antiplatelet
        • 5.2.4.2. Tissue Plasminogen Activator
        • 5.2.4.3. Antihypertensive
        • 5.2.4.4. Anticoagulant
      • 5.2.5. Global Stroke Management by: Devices (Value)
        • 5.2.5.1. Stent Retriever
        • 5.2.5.2. Surgical Clipping
        • 5.2.5.3. Embolic Coils
        • 5.2.5.4. Flow Diverters
        • 5.2.5.5. Aspiration Catheters
      • 5.2.6. Global Stroke Management Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Stroke Management: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GE Healthcare (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Siemens Healthineers AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Koninklijke Philips N.V. (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Toshiba Corporation (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shimadzu Corporation (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hitachi, Ltd. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Neurologica Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Neusoft Medical Systems Co. Ltd. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shenzhen Anke High-tech Co. (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Shanghai United Imaging Healthcare Co. Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Stroke Management Sale, by Type, Application, Diagnostics, Therapeutics, Devices and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Stroke Management (Value)
      • 7.2.1. Global Stroke Management by: Type (Value)
        • 7.2.1.1. Ischemic
        • 7.2.1.2. Hemorrhagic
        • 7.2.1.3. Transient Ischemic Attack [TIA])
      • 7.2.2. Global Stroke Management by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgery Centers
        • 7.2.2.3. Diagnostic Centers
      • 7.2.3. Global Stroke Management by: Diagnostics (Value)
        • 7.2.3.1. Magnetic Resonance Imaging [MRI]
        • 7.2.3.2. Computed Tomography Scan [CT Scan]
        • 7.2.3.3. Electrocardiography
        • 7.2.3.4. Carotid Ultrasound
        • 7.2.3.5. Cerebral Angiography
        • 7.2.3.6. Others
      • 7.2.4. Global Stroke Management by: Therapeutics (Value)
        • 7.2.4.1. Antiplatelet
        • 7.2.4.2. Tissue Plasminogen Activator
        • 7.2.4.3. Antihypertensive
        • 7.2.4.4. Anticoagulant
      • 7.2.5. Global Stroke Management by: Devices (Value)
        • 7.2.5.1. Stent Retriever
        • 7.2.5.2. Surgical Clipping
        • 7.2.5.3. Embolic Coils
        • 7.2.5.4. Flow Diverters
        • 7.2.5.5. Aspiration Catheters
      • 7.2.6. Global Stroke Management Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Stroke Management: by Type(USD Billion)
  • Table 2. Stroke Management Ischemic , by Region USD Billion (2016-2021)
  • Table 3. Stroke Management Hemorrhagic , by Region USD Billion (2016-2021)
  • Table 4. Stroke Management Transient Ischemic Attack [TIA]) , by Region USD Billion (2016-2021)
  • Table 5. Stroke Management: by Application(USD Billion)
  • Table 6. Stroke Management Hospitals , by Region USD Billion (2016-2021)
  • Table 7. Stroke Management Ambulatory Surgery Centers , by Region USD Billion (2016-2021)
  • Table 8. Stroke Management Diagnostic Centers , by Region USD Billion (2016-2021)
  • Table 9. Stroke Management: by Diagnostics(USD Billion)
  • Table 10. Stroke Management Magnetic Resonance Imaging [MRI] , by Region USD Billion (2016-2021)
  • Table 11. Stroke Management Computed Tomography Scan [CT Scan] , by Region USD Billion (2016-2021)
  • Table 12. Stroke Management Electrocardiography , by Region USD Billion (2016-2021)
  • Table 13. Stroke Management Carotid Ultrasound , by Region USD Billion (2016-2021)
  • Table 14. Stroke Management Cerebral Angiography , by Region USD Billion (2016-2021)
  • Table 15. Stroke Management Others , by Region USD Billion (2016-2021)
  • Table 16. Stroke Management: by Therapeutics(USD Billion)
  • Table 17. Stroke Management Antiplatelet , by Region USD Billion (2016-2021)
  • Table 18. Stroke Management Tissue Plasminogen Activator , by Region USD Billion (2016-2021)
  • Table 19. Stroke Management Antihypertensive , by Region USD Billion (2016-2021)
  • Table 20. Stroke Management Anticoagulant , by Region USD Billion (2016-2021)
  • Table 21. Stroke Management: by Devices(USD Billion)
  • Table 22. Stroke Management Stent Retriever , by Region USD Billion (2016-2021)
  • Table 23. Stroke Management Surgical Clipping , by Region USD Billion (2016-2021)
  • Table 24. Stroke Management Embolic Coils , by Region USD Billion (2016-2021)
  • Table 25. Stroke Management Flow Diverters , by Region USD Billion (2016-2021)
  • Table 26. Stroke Management Aspiration Catheters , by Region USD Billion (2016-2021)
  • Table 27. South America Stroke Management, by Country USD Billion (2016-2021)
  • Table 28. South America Stroke Management, by Type USD Billion (2016-2021)
  • Table 29. South America Stroke Management, by Application USD Billion (2016-2021)
  • Table 30. South America Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 31. South America Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 32. South America Stroke Management, by Devices USD Billion (2016-2021)
  • Table 33. Brazil Stroke Management, by Type USD Billion (2016-2021)
  • Table 34. Brazil Stroke Management, by Application USD Billion (2016-2021)
  • Table 35. Brazil Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 36. Brazil Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 37. Brazil Stroke Management, by Devices USD Billion (2016-2021)
  • Table 38. Argentina Stroke Management, by Type USD Billion (2016-2021)
  • Table 39. Argentina Stroke Management, by Application USD Billion (2016-2021)
  • Table 40. Argentina Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 41. Argentina Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 42. Argentina Stroke Management, by Devices USD Billion (2016-2021)
  • Table 43. Rest of South America Stroke Management, by Type USD Billion (2016-2021)
  • Table 44. Rest of South America Stroke Management, by Application USD Billion (2016-2021)
  • Table 45. Rest of South America Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 46. Rest of South America Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 47. Rest of South America Stroke Management, by Devices USD Billion (2016-2021)
  • Table 48. Asia Pacific Stroke Management, by Country USD Billion (2016-2021)
  • Table 49. Asia Pacific Stroke Management, by Type USD Billion (2016-2021)
  • Table 50. Asia Pacific Stroke Management, by Application USD Billion (2016-2021)
  • Table 51. Asia Pacific Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 52. Asia Pacific Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 53. Asia Pacific Stroke Management, by Devices USD Billion (2016-2021)
  • Table 54. China Stroke Management, by Type USD Billion (2016-2021)
  • Table 55. China Stroke Management, by Application USD Billion (2016-2021)
  • Table 56. China Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 57. China Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 58. China Stroke Management, by Devices USD Billion (2016-2021)
  • Table 59. Japan Stroke Management, by Type USD Billion (2016-2021)
  • Table 60. Japan Stroke Management, by Application USD Billion (2016-2021)
  • Table 61. Japan Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 62. Japan Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 63. Japan Stroke Management, by Devices USD Billion (2016-2021)
  • Table 64. India Stroke Management, by Type USD Billion (2016-2021)
  • Table 65. India Stroke Management, by Application USD Billion (2016-2021)
  • Table 66. India Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 67. India Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 68. India Stroke Management, by Devices USD Billion (2016-2021)
  • Table 69. South Korea Stroke Management, by Type USD Billion (2016-2021)
  • Table 70. South Korea Stroke Management, by Application USD Billion (2016-2021)
  • Table 71. South Korea Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 72. South Korea Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 73. South Korea Stroke Management, by Devices USD Billion (2016-2021)
  • Table 74. Taiwan Stroke Management, by Type USD Billion (2016-2021)
  • Table 75. Taiwan Stroke Management, by Application USD Billion (2016-2021)
  • Table 76. Taiwan Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 77. Taiwan Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 78. Taiwan Stroke Management, by Devices USD Billion (2016-2021)
  • Table 79. Australia Stroke Management, by Type USD Billion (2016-2021)
  • Table 80. Australia Stroke Management, by Application USD Billion (2016-2021)
  • Table 81. Australia Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 82. Australia Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 83. Australia Stroke Management, by Devices USD Billion (2016-2021)
  • Table 84. Rest of Asia-Pacific Stroke Management, by Type USD Billion (2016-2021)
  • Table 85. Rest of Asia-Pacific Stroke Management, by Application USD Billion (2016-2021)
  • Table 86. Rest of Asia-Pacific Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 87. Rest of Asia-Pacific Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 88. Rest of Asia-Pacific Stroke Management, by Devices USD Billion (2016-2021)
  • Table 89. Europe Stroke Management, by Country USD Billion (2016-2021)
  • Table 90. Europe Stroke Management, by Type USD Billion (2016-2021)
  • Table 91. Europe Stroke Management, by Application USD Billion (2016-2021)
  • Table 92. Europe Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 93. Europe Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 94. Europe Stroke Management, by Devices USD Billion (2016-2021)
  • Table 95. Germany Stroke Management, by Type USD Billion (2016-2021)
  • Table 96. Germany Stroke Management, by Application USD Billion (2016-2021)
  • Table 97. Germany Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 98. Germany Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 99. Germany Stroke Management, by Devices USD Billion (2016-2021)
  • Table 100. France Stroke Management, by Type USD Billion (2016-2021)
  • Table 101. France Stroke Management, by Application USD Billion (2016-2021)
  • Table 102. France Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 103. France Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 104. France Stroke Management, by Devices USD Billion (2016-2021)
  • Table 105. Italy Stroke Management, by Type USD Billion (2016-2021)
  • Table 106. Italy Stroke Management, by Application USD Billion (2016-2021)
  • Table 107. Italy Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 108. Italy Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 109. Italy Stroke Management, by Devices USD Billion (2016-2021)
  • Table 110. United Kingdom Stroke Management, by Type USD Billion (2016-2021)
  • Table 111. United Kingdom Stroke Management, by Application USD Billion (2016-2021)
  • Table 112. United Kingdom Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 113. United Kingdom Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 114. United Kingdom Stroke Management, by Devices USD Billion (2016-2021)
  • Table 115. Netherlands Stroke Management, by Type USD Billion (2016-2021)
  • Table 116. Netherlands Stroke Management, by Application USD Billion (2016-2021)
  • Table 117. Netherlands Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 118. Netherlands Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 119. Netherlands Stroke Management, by Devices USD Billion (2016-2021)
  • Table 120. Rest of Europe Stroke Management, by Type USD Billion (2016-2021)
  • Table 121. Rest of Europe Stroke Management, by Application USD Billion (2016-2021)
  • Table 122. Rest of Europe Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 123. Rest of Europe Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 124. Rest of Europe Stroke Management, by Devices USD Billion (2016-2021)
  • Table 125. MEA Stroke Management, by Country USD Billion (2016-2021)
  • Table 126. MEA Stroke Management, by Type USD Billion (2016-2021)
  • Table 127. MEA Stroke Management, by Application USD Billion (2016-2021)
  • Table 128. MEA Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 129. MEA Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 130. MEA Stroke Management, by Devices USD Billion (2016-2021)
  • Table 131. Middle East Stroke Management, by Type USD Billion (2016-2021)
  • Table 132. Middle East Stroke Management, by Application USD Billion (2016-2021)
  • Table 133. Middle East Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 134. Middle East Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 135. Middle East Stroke Management, by Devices USD Billion (2016-2021)
  • Table 136. Africa Stroke Management, by Type USD Billion (2016-2021)
  • Table 137. Africa Stroke Management, by Application USD Billion (2016-2021)
  • Table 138. Africa Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 139. Africa Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 140. Africa Stroke Management, by Devices USD Billion (2016-2021)
  • Table 141. North America Stroke Management, by Country USD Billion (2016-2021)
  • Table 142. North America Stroke Management, by Type USD Billion (2016-2021)
  • Table 143. North America Stroke Management, by Application USD Billion (2016-2021)
  • Table 144. North America Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 145. North America Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 146. North America Stroke Management, by Devices USD Billion (2016-2021)
  • Table 147. United States Stroke Management, by Type USD Billion (2016-2021)
  • Table 148. United States Stroke Management, by Application USD Billion (2016-2021)
  • Table 149. United States Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 150. United States Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 151. United States Stroke Management, by Devices USD Billion (2016-2021)
  • Table 152. Canada Stroke Management, by Type USD Billion (2016-2021)
  • Table 153. Canada Stroke Management, by Application USD Billion (2016-2021)
  • Table 154. Canada Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 155. Canada Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 156. Canada Stroke Management, by Devices USD Billion (2016-2021)
  • Table 157. Mexico Stroke Management, by Type USD Billion (2016-2021)
  • Table 158. Mexico Stroke Management, by Application USD Billion (2016-2021)
  • Table 159. Mexico Stroke Management, by Diagnostics USD Billion (2016-2021)
  • Table 160. Mexico Stroke Management, by Therapeutics USD Billion (2016-2021)
  • Table 161. Mexico Stroke Management, by Devices USD Billion (2016-2021)
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Stroke Management: by Type(USD Billion)
  • Table 173. Stroke Management Ischemic , by Region USD Billion (2022-2027)
  • Table 174. Stroke Management Hemorrhagic , by Region USD Billion (2022-2027)
  • Table 175. Stroke Management Transient Ischemic Attack [TIA]) , by Region USD Billion (2022-2027)
  • Table 176. Stroke Management: by Application(USD Billion)
  • Table 177. Stroke Management Hospitals , by Region USD Billion (2022-2027)
  • Table 178. Stroke Management Ambulatory Surgery Centers , by Region USD Billion (2022-2027)
  • Table 179. Stroke Management Diagnostic Centers , by Region USD Billion (2022-2027)
  • Table 180. Stroke Management: by Diagnostics(USD Billion)
  • Table 181. Stroke Management Magnetic Resonance Imaging [MRI] , by Region USD Billion (2022-2027)
  • Table 182. Stroke Management Computed Tomography Scan [CT Scan] , by Region USD Billion (2022-2027)
  • Table 183. Stroke Management Electrocardiography , by Region USD Billion (2022-2027)
  • Table 184. Stroke Management Carotid Ultrasound , by Region USD Billion (2022-2027)
  • Table 185. Stroke Management Cerebral Angiography , by Region USD Billion (2022-2027)
  • Table 186. Stroke Management Others , by Region USD Billion (2022-2027)
  • Table 187. Stroke Management: by Therapeutics(USD Billion)
  • Table 188. Stroke Management Antiplatelet , by Region USD Billion (2022-2027)
  • Table 189. Stroke Management Tissue Plasminogen Activator , by Region USD Billion (2022-2027)
  • Table 190. Stroke Management Antihypertensive , by Region USD Billion (2022-2027)
  • Table 191. Stroke Management Anticoagulant , by Region USD Billion (2022-2027)
  • Table 192. Stroke Management: by Devices(USD Billion)
  • Table 193. Stroke Management Stent Retriever , by Region USD Billion (2022-2027)
  • Table 194. Stroke Management Surgical Clipping , by Region USD Billion (2022-2027)
  • Table 195. Stroke Management Embolic Coils , by Region USD Billion (2022-2027)
  • Table 196. Stroke Management Flow Diverters , by Region USD Billion (2022-2027)
  • Table 197. Stroke Management Aspiration Catheters , by Region USD Billion (2022-2027)
  • Table 198. South America Stroke Management, by Country USD Billion (2022-2027)
  • Table 199. South America Stroke Management, by Type USD Billion (2022-2027)
  • Table 200. South America Stroke Management, by Application USD Billion (2022-2027)
  • Table 201. South America Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 202. South America Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 203. South America Stroke Management, by Devices USD Billion (2022-2027)
  • Table 204. Brazil Stroke Management, by Type USD Billion (2022-2027)
  • Table 205. Brazil Stroke Management, by Application USD Billion (2022-2027)
  • Table 206. Brazil Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 207. Brazil Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 208. Brazil Stroke Management, by Devices USD Billion (2022-2027)
  • Table 209. Argentina Stroke Management, by Type USD Billion (2022-2027)
  • Table 210. Argentina Stroke Management, by Application USD Billion (2022-2027)
  • Table 211. Argentina Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 212. Argentina Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 213. Argentina Stroke Management, by Devices USD Billion (2022-2027)
  • Table 214. Rest of South America Stroke Management, by Type USD Billion (2022-2027)
  • Table 215. Rest of South America Stroke Management, by Application USD Billion (2022-2027)
  • Table 216. Rest of South America Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 217. Rest of South America Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 218. Rest of South America Stroke Management, by Devices USD Billion (2022-2027)
  • Table 219. Asia Pacific Stroke Management, by Country USD Billion (2022-2027)
  • Table 220. Asia Pacific Stroke Management, by Type USD Billion (2022-2027)
  • Table 221. Asia Pacific Stroke Management, by Application USD Billion (2022-2027)
  • Table 222. Asia Pacific Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 223. Asia Pacific Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 224. Asia Pacific Stroke Management, by Devices USD Billion (2022-2027)
  • Table 225. China Stroke Management, by Type USD Billion (2022-2027)
  • Table 226. China Stroke Management, by Application USD Billion (2022-2027)
  • Table 227. China Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 228. China Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 229. China Stroke Management, by Devices USD Billion (2022-2027)
  • Table 230. Japan Stroke Management, by Type USD Billion (2022-2027)
  • Table 231. Japan Stroke Management, by Application USD Billion (2022-2027)
  • Table 232. Japan Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 233. Japan Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 234. Japan Stroke Management, by Devices USD Billion (2022-2027)
  • Table 235. India Stroke Management, by Type USD Billion (2022-2027)
  • Table 236. India Stroke Management, by Application USD Billion (2022-2027)
  • Table 237. India Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 238. India Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 239. India Stroke Management, by Devices USD Billion (2022-2027)
  • Table 240. South Korea Stroke Management, by Type USD Billion (2022-2027)
  • Table 241. South Korea Stroke Management, by Application USD Billion (2022-2027)
  • Table 242. South Korea Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 243. South Korea Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 244. South Korea Stroke Management, by Devices USD Billion (2022-2027)
  • Table 245. Taiwan Stroke Management, by Type USD Billion (2022-2027)
  • Table 246. Taiwan Stroke Management, by Application USD Billion (2022-2027)
  • Table 247. Taiwan Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 248. Taiwan Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 249. Taiwan Stroke Management, by Devices USD Billion (2022-2027)
  • Table 250. Australia Stroke Management, by Type USD Billion (2022-2027)
  • Table 251. Australia Stroke Management, by Application USD Billion (2022-2027)
  • Table 252. Australia Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 253. Australia Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 254. Australia Stroke Management, by Devices USD Billion (2022-2027)
  • Table 255. Rest of Asia-Pacific Stroke Management, by Type USD Billion (2022-2027)
  • Table 256. Rest of Asia-Pacific Stroke Management, by Application USD Billion (2022-2027)
  • Table 257. Rest of Asia-Pacific Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 258. Rest of Asia-Pacific Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 259. Rest of Asia-Pacific Stroke Management, by Devices USD Billion (2022-2027)
  • Table 260. Europe Stroke Management, by Country USD Billion (2022-2027)
  • Table 261. Europe Stroke Management, by Type USD Billion (2022-2027)
  • Table 262. Europe Stroke Management, by Application USD Billion (2022-2027)
  • Table 263. Europe Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 264. Europe Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 265. Europe Stroke Management, by Devices USD Billion (2022-2027)
  • Table 266. Germany Stroke Management, by Type USD Billion (2022-2027)
  • Table 267. Germany Stroke Management, by Application USD Billion (2022-2027)
  • Table 268. Germany Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 269. Germany Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 270. Germany Stroke Management, by Devices USD Billion (2022-2027)
  • Table 271. France Stroke Management, by Type USD Billion (2022-2027)
  • Table 272. France Stroke Management, by Application USD Billion (2022-2027)
  • Table 273. France Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 274. France Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 275. France Stroke Management, by Devices USD Billion (2022-2027)
  • Table 276. Italy Stroke Management, by Type USD Billion (2022-2027)
  • Table 277. Italy Stroke Management, by Application USD Billion (2022-2027)
  • Table 278. Italy Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 279. Italy Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 280. Italy Stroke Management, by Devices USD Billion (2022-2027)
  • Table 281. United Kingdom Stroke Management, by Type USD Billion (2022-2027)
  • Table 282. United Kingdom Stroke Management, by Application USD Billion (2022-2027)
  • Table 283. United Kingdom Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 284. United Kingdom Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 285. United Kingdom Stroke Management, by Devices USD Billion (2022-2027)
  • Table 286. Netherlands Stroke Management, by Type USD Billion (2022-2027)
  • Table 287. Netherlands Stroke Management, by Application USD Billion (2022-2027)
  • Table 288. Netherlands Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 289. Netherlands Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 290. Netherlands Stroke Management, by Devices USD Billion (2022-2027)
  • Table 291. Rest of Europe Stroke Management, by Type USD Billion (2022-2027)
  • Table 292. Rest of Europe Stroke Management, by Application USD Billion (2022-2027)
  • Table 293. Rest of Europe Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 294. Rest of Europe Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 295. Rest of Europe Stroke Management, by Devices USD Billion (2022-2027)
  • Table 296. MEA Stroke Management, by Country USD Billion (2022-2027)
  • Table 297. MEA Stroke Management, by Type USD Billion (2022-2027)
  • Table 298. MEA Stroke Management, by Application USD Billion (2022-2027)
  • Table 299. MEA Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 300. MEA Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 301. MEA Stroke Management, by Devices USD Billion (2022-2027)
  • Table 302. Middle East Stroke Management, by Type USD Billion (2022-2027)
  • Table 303. Middle East Stroke Management, by Application USD Billion (2022-2027)
  • Table 304. Middle East Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 305. Middle East Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 306. Middle East Stroke Management, by Devices USD Billion (2022-2027)
  • Table 307. Africa Stroke Management, by Type USD Billion (2022-2027)
  • Table 308. Africa Stroke Management, by Application USD Billion (2022-2027)
  • Table 309. Africa Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 310. Africa Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 311. Africa Stroke Management, by Devices USD Billion (2022-2027)
  • Table 312. North America Stroke Management, by Country USD Billion (2022-2027)
  • Table 313. North America Stroke Management, by Type USD Billion (2022-2027)
  • Table 314. North America Stroke Management, by Application USD Billion (2022-2027)
  • Table 315. North America Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 316. North America Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 317. North America Stroke Management, by Devices USD Billion (2022-2027)
  • Table 318. United States Stroke Management, by Type USD Billion (2022-2027)
  • Table 319. United States Stroke Management, by Application USD Billion (2022-2027)
  • Table 320. United States Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 321. United States Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 322. United States Stroke Management, by Devices USD Billion (2022-2027)
  • Table 323. Canada Stroke Management, by Type USD Billion (2022-2027)
  • Table 324. Canada Stroke Management, by Application USD Billion (2022-2027)
  • Table 325. Canada Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 326. Canada Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 327. Canada Stroke Management, by Devices USD Billion (2022-2027)
  • Table 328. Mexico Stroke Management, by Type USD Billion (2022-2027)
  • Table 329. Mexico Stroke Management, by Application USD Billion (2022-2027)
  • Table 330. Mexico Stroke Management, by Diagnostics USD Billion (2022-2027)
  • Table 331. Mexico Stroke Management, by Therapeutics USD Billion (2022-2027)
  • Table 332. Mexico Stroke Management, by Devices USD Billion (2022-2027)
  • Table 333. Research Programs/Design for This Report
  • Table 334. Key Data Information from Secondary Sources
  • Table 335. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Stroke Management: by Type USD Billion (2016-2021)
  • Figure 5. Global Stroke Management: by Application USD Billion (2016-2021)
  • Figure 6. Global Stroke Management: by Diagnostics USD Billion (2016-2021)
  • Figure 7. Global Stroke Management: by Therapeutics USD Billion (2016-2021)
  • Figure 8. Global Stroke Management: by Devices USD Billion (2016-2021)
  • Figure 9. South America Stroke Management Share (%), by Country
  • Figure 10. Asia Pacific Stroke Management Share (%), by Country
  • Figure 11. Europe Stroke Management Share (%), by Country
  • Figure 12. MEA Stroke Management Share (%), by Country
  • Figure 13. North America Stroke Management Share (%), by Country
  • Figure 14. Global Stroke Management share by Players 2021 (%)
  • Figure 15. Global Stroke Management share by Players (Top 3) 2021(%)
  • Figure 16. Global Stroke Management share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 19. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 20. Siemens Healthineers AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Siemens Healthineers AG (Germany) Revenue: by Geography 2021
  • Figure 22. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 23. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2021
  • Figure 24. Toshiba Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Toshiba Corporation (Japan) Revenue: by Geography 2021
  • Figure 26. Shimadzu Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Shimadzu Corporation (Japan) Revenue: by Geography 2021
  • Figure 28. Hitachi, Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Hitachi, Ltd. (Japan) Revenue: by Geography 2021
  • Figure 30. Neurologica Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 31. Neurologica Corporation (United States) Revenue: by Geography 2021
  • Figure 32. Neusoft Medical Systems Co. Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 33. Neusoft Medical Systems Co. Ltd. (China) Revenue: by Geography 2021
  • Figure 34. Shenzhen Anke High-tech Co. (China) Revenue, Net Income and Gross profit
  • Figure 35. Shenzhen Anke High-tech Co. (China) Revenue: by Geography 2021
  • Figure 36. Shanghai United Imaging Healthcare Co. Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 37. Shanghai United Imaging Healthcare Co. Ltd. (China) Revenue: by Geography 2021
  • Figure 38. Global Stroke Management: by Type USD Billion (2022-2027)
  • Figure 39. Global Stroke Management: by Application USD Billion (2022-2027)
  • Figure 40. Global Stroke Management: by Diagnostics USD Billion (2022-2027)
  • Figure 41. Global Stroke Management: by Therapeutics USD Billion (2022-2027)
  • Figure 42. Global Stroke Management: by Devices USD Billion (2022-2027)
  • Figure 43. South America Stroke Management Share (%), by Country
  • Figure 44. Asia Pacific Stroke Management Share (%), by Country
  • Figure 45. Europe Stroke Management Share (%), by Country
  • Figure 46. MEA Stroke Management Share (%), by Country
  • Figure 47. North America Stroke Management Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GE Healthcare (United States)
  • Siemens Healthineers AG (Germany)
  • Koninklijke Philips N.V. (Netherlands)
  • Toshiba Corporation (Japan)
  • Shimadzu Corporation (Japan)
  • Hitachi, Ltd. (Japan)
  • Neurologica Corporation (United States)
  • Neusoft Medical Systems Co. Ltd. (China)
  • Shenzhen Anke High-tech Co. (China)
  • Shanghai United Imaging Healthcare Co. Ltd. (China)
Additional players considered in the study are as follows:
Abbott Laboratories (United States) , B. Braun Melsungen AG (Germany) , Boston Scientific Corporation (United States) , Bristol-Myers Squibb Company (United States) , Medtronic plc (Ireland) , Cardinal Health, Inc. (United States) , GlaxoSmithKline plc (United Kingdom) , Merck & Co. Inc. (United States)
Select User Access Type

Key Highlights of Report


Jun 2021 221 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Stroke Management Quantitative research analysis
Global Stroke Management Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Stroke Management market are GE Healthcare (United States), Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), Toshiba Corporation (Japan), Shimadzu Corporation (Japan), Hitachi, Ltd. (Japan), Neurologica Corporation (United States), Neusoft Medical Systems Co. Ltd. (China), Shenzhen Anke High-tech Co. (China) and Shanghai United Imaging Healthcare Co. Ltd. (China), to name a few.
North Amercia is dominating the Stroke Management Market.
"Operational Complexities and the Dearth of Skilled Researchers " is seen as one of the major challenges by many Industry Players of Stroke Management Market
The Stroke Management market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Stroke Management market is expected to see a steady growth rate during projected year 2021 to 2027.

Know More About Global Stroke Management Report?

Have a Query? Click Here

Other Related Reports

Hybrid Operating Room Technology Comprehensive Study by Type (Intraoperative Diagnostic imaging systems (Angiography systems, MRI systems, CT systems, Other), Operating room fixtures (Operating table...
$ 3750
IT Spending on Clinical Analytics Comprehensive Study by Platform (Stand-alone, Integrated), Solutions (In-house (Hardware, Software, Services), Outsource), Deployment Type (Cloud-based, On-premise),...
$ 3450
IoT in Healthcare Comprehensive Study by Application (Telemedicine, Clinical operations and workflow management, Connected Imaging, Inpatient Monitoring, Medication Management, Others), Component (Me...
$ 3750
Facial Erythema Treatment Comprehensive Study by Type (Erythematotelangiectatic (ETR), Papulopustular (PPR), Phymatous, Ocular), Application (Dermatology Clinics, Beauty Salon, Others), Drug Type (Em...
$ 3650
Medical Baby Monitoring Device Comprehensive Study by Type (Video Monitor, Breathing Monitor, Movement Monitor, Audio Monitor, Breathing Monitor, Movement Monitor, Other), Application (Hospitals, Fam...
$ 3450
Practice Management System Comprehensive Study by Type (Integrated, Standalone), Components (Services, Software), Delivery Mode (On-Premises, Web-Based, Cloud-Based), End-Users (Physicians, Pharmacis...
$ 3350